H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on HUMA stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that indicate potential growth and positive future prospects for Humacyte. The significant increase in value analysis committee (VAC) approvals for Symvess is a strong indicator of future product adoption, suggesting a promising sales trajectory for 2026. Additionally, the expansion of civilian hospitals eligible to purchase Symvess further supports this positive outlook.
Moreover, the upcoming interim data from the V012 study, expected in April 2026, is anticipated to act as a significant catalyst. The successful enrollment and progress of this Phase 3 study, along with the potential for an expanded market beyond the current limited approval, reinforce the potential for increased revenue. Financially, Humacyte’s recent cash inflow is deemed sufficient to support operations into the second half of 2026, providing a stable financial foundation. These factors collectively contribute to the Buy rating, with a calculated price target of $3.00 based on risk-adjusted net present value analysis.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $3.50 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUMA in relation to earlier this year.